Human IL-17A&IL-17F Heterodimer Protein, His Tag&Strep II Tag
Proteins and Peptides
- 貨號 Cat. No.
- ILF-H52WF
- 規格 Size
- 1mg
- 品牌 Brand
- ACROBiosystems
- Species
- Human
- Conjugate
- Unconjugated
- Expression System
- HEK293
- Tag
- His Tag 、 Strep Tag
Description
Source :
Human IL-17A&IL-17F Heterodimer Protein, His Tag&Strep II Tag (ILF-H52WF) is expressed from human 293 cells (HEK293). It contains AA Gly 24 - Ala 155 (IL-17A) & Arg 31 - Gln 163 (IL-17F) (Accession # Q16552-1 (IL-17A) & Q96PD4-1 (IL-17F)). Two sequential affinity purification steps were used to ensure exact 1:1 molar ratio of IL17A&IL17F heterodimer.
Molecule : IL-17A & IL-17F
Synonyms : IL-17A,Interleukin-17A,CTLA-8,IL-17,IL-17F,IL24,ML-1,Interleukin-17F
Format : Powder
Category : Cytokines&Growth Factors
Accession : NP_002181.1 (IL-17A) & NP_443104.1 (IL-17F)
Storage : -20℃
Shipping condition : Powder,RT
Molecular Weight : 17.0 kDa (IL-17A) & 18.4 kDa (IL-17F)
Characteristics :
Human IL-17A&IL-17F Heterodimer Protein, His Tag&Strep II Tag, produced by co-expression of IL-17A and IL-17F, has a calculated MW of 17.0 kDa (IL-17A) and 18.4 kDa (IL-17F). Subunit IL-17A is fused with a polyhistidine tag at the N-terminus and subunit I
Endotoxin Level : Less than 1.0 EU per μg by the LAL method.
Buffer : PBS, pH7.4
Description :
Interleukin-17A (IL17A) is also known as cytotoxic T-lymphocyte-associated antigen 8 (CTLA8),which is a proinflammatory cytokine produced by activated T cells. IL17A can regulate the activities of NF-kappaB and mitogen-activated protein kinases. Also,IL17A can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO).Furthermore,IL17A has been found both in glycosylated and nonglycosylated forms. High levels of IL-17 are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis.
References :
(1) Yao Z., et al.,1995, J. Immunol. 155:5483-5486.
(2) Gerhardt S., et al., 2009, J. Mol. Biol. 394:905-921.

